196 related articles for article (PubMed ID: 7083725)
21. Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis.
Pancorbo S; Comty C
Antimicrob Agents Chemother; 1981 Apr; 19(4):605-7. PubMed ID: 7247382
[TBL] [Abstract][Full Text] [Related]
22. Vestibular toxicity due to gentamicin in peritoneal dialysis patients.
Chong TK; Piraino B; Bernardini J
Perit Dial Int; 1991; 11(2):152-5. PubMed ID: 1854873
[TBL] [Abstract][Full Text] [Related]
23. Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis.
Bunke CM; Aronoff GR; Brier ME; Sloan RS; Luft FC
Clin Pharmacol Ther; 1983 Jan; 33(1):66-72. PubMed ID: 6848301
[TBL] [Abstract][Full Text] [Related]
24. A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD).
Friedland JS; Iveson TJ; Fraise AP; Winearls CG; Selkon JB; Oliver DO
J Antimicrob Chemother; 1990 Dec; 26 Suppl F():77-81. PubMed ID: 2292548
[TBL] [Abstract][Full Text] [Related]
25. Cefotaxime and metabolite disposition in two pediatric continuous ambulatory peritoneal dialysis patients.
Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JA
Ann Pharmacother; 1992 Mar; 26(3):341-3. PubMed ID: 1554953
[TBL] [Abstract][Full Text] [Related]
26. Vancomycin disposition during continuous ambulatory peritoneal dialysis: a pharmacokinetic analysis of peritoneal drug transport.
Rogge MC; Johnson CA; Zimmerman SW; Welling PG
Antimicrob Agents Chemother; 1985 Apr; 27(4):578-82. PubMed ID: 4004194
[TBL] [Abstract][Full Text] [Related]
27. Vancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysis.
Blowey DL; Warady BA; Abdel-Rahman S; Frye RF; Manley HJ
Perit Dial Int; 2007; 27(1):79-85. PubMed ID: 17179516
[TBL] [Abstract][Full Text] [Related]
28. Systemic absorption of intraperitoneal antimicrobials in continuous ambulatory peritoneal dialysis.
O'Brien MA; Mason NA
Clin Pharm; 1992 Mar; 11(3):246-54. PubMed ID: 1611814
[TBL] [Abstract][Full Text] [Related]
29. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.
Keller E; Reetze P; Schollmeyer P
Clin Pharmacokinet; 1990 Feb; 18(2):104-17. PubMed ID: 2180611
[TBL] [Abstract][Full Text] [Related]
30. Gentamicin removal during intermittent peritoneal dialysis.
Indraprasit S; Ukaravichien V; Pummangura C; Kaojarern S
Nephron; 1986; 44(1):18-21. PubMed ID: 3748247
[TBL] [Abstract][Full Text] [Related]
31. Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients.
Yamagata K; Tomida C; Koyama A
Perit Dial Int; 1999; 19(2):131-7. PubMed ID: 10357183
[TBL] [Abstract][Full Text] [Related]
32. Single UK centre experience on the treatment of PD peritonitis--antibiotic levels and outcomes.
Blunden M; Zeitlin D; Ashman N; Fan SL
Nephrol Dial Transplant; 2007 Jun; 22(6):1714-9. PubMed ID: 17369615
[TBL] [Abstract][Full Text] [Related]
33. Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nikolaidis P; Walker SE; Dombros N; Tourkantonis A; Paton TW; Oreopoulos DG
Perit Dial Int; 1991; 11(1):59-63. PubMed ID: 2049424
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis.
Demotes-Mainard F; Vinçon G; Ragnaud JM; Morlat P; Bannwarth B; Dangoumau J
J Clin Pharmacol; 1993 May; 33(5):475-9. PubMed ID: 8331207
[TBL] [Abstract][Full Text] [Related]
35. Serum and dialyzate concentrations of intraperitoneal cephalothin in patients undergoing continuous ambulatory peritoneal dialysis.
Münch R; Steurer J; Lüthy R; Siegenthaler W; Kuhlmann U
Clin Nephrol; 1983 Jul; 20(1):40-3. PubMed ID: 6883818
[TBL] [Abstract][Full Text] [Related]
36. Prostaglandin inhibition by intraperitoneal indomethacin has no effect on peritoneal permeability during stable CAPD.
Douma CE; de Waart DR; Zemel D; Struijk DG; Krediet RT
Nephrol Dial Transplant; 2001 Apr; 16(4):803-8. PubMed ID: 11274278
[TBL] [Abstract][Full Text] [Related]
37. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
Gerig JS; Bolton ND; Swabb EA; Scheld WM; Bolton WK
Kidney Int; 1984 Sep; 26(3):308-18. PubMed ID: 6542606
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of cefotaxime in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis.
Hasegawa H; Imada A; Horiuchi A; Nishii Y; Fukushima M; Kurokawa E
J Antimicrob Chemother; 1984 Sep; 14 Suppl B():135-42. PubMed ID: 6094432
[TBL] [Abstract][Full Text] [Related]
39. The effect of peritonitis on the transperitoneal transport of cefuroxime in patients on CAPD treatment.
Dahl K; Walstad RA; Widerøe TE
Nephrol Dial Transplant; 1990; 5(4):275-81. PubMed ID: 2113224
[TBL] [Abstract][Full Text] [Related]
40. Vancomycin and netilmicin as first line treatment of peritonitis in CAPD patients.
Brauner L; Kahlmeter G; Lindholm T; Simonsen O
J Antimicrob Chemother; 1985 Jun; 15(6):751-8. PubMed ID: 4030537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
